New policy priorities are shaping both advertising campaigns and regulatory oversight. Increasingly, parties are turning to NAD to address pharmaceutical advertising and claims addressing serious medical conditions. This panel will discuss the shifting policy landscape, practical substantiation approaches, and common pitfalls in advertising in this high-impact space.